Likewise, in the context of PD-L1 expression mediated by HRD, BRCA1 mutated breast cancer has been demonstrated to have a higher PD-L1 tumor score than BRCA2 mutated, even though clinical efficacy is inferior (41, 54). Here, BRCA1 is linked to breast cancer.